# EDGAR Filing Document

**Accession Number:** 0001828673
**File Stem:** 0000950170-25-089035
**Filing Date:** 2025-6
**Character Count:** 9159
**Document Hash:** a71fb272bb3201f6f7e939ab0a81a04d
**Contains OCR:** False
**Source Format:** 

## Filing Content

## Filing Summary
**0000950170-25-089035.hdr.sgml**: 20250623

**ACCESSION NUMBER**: 0000950170-25-089035

**CONFORMED SUBMISSION TYPE**: 8-K

**PUBLIC DOCUMENT COUNT**: 12

**CONFORMED PERIOD OF REPORT**: 20250617

**ITEM INFORMATION**: Departure of Directors or Certain Officers; Election of Directors; Appointment of Certain Officers: Compensatory Arrangements of Certain Officers

**ITEM INFORMATION**: Submission of Matters to a Vote of Security Holders

**ITEM INFORMATION**: Other Events

**ITEM INFORMATION**: Financial Statements and Exhibits

**FILED AS OF DATE**: 20250623

**DATE AS OF CHANGE**: 20250623

**FILER**: 

**COMPANY DATA:**
- **COMPANY CONFORMED NAME:** HCW Biologics Inc.
- **CENTRAL INDEX KEY:** 0001828673
- **STANDARD INDUSTRIAL CLASSIFICATION:** PHARMACEUTICAL PREPARATIONS [2834]
- **ORGANIZATION NAME:** 03 Life Sciences
- **EIN:** 825024477
- **STATE OF INCORPORATION:** DE
- **FISCAL YEAR END:** 1231

**FILING VALUES:**
- **FORM TYPE:** 8-K
- **SEC ACT:** 1934 Act
- **SEC FILE NUMBER:** 001-40591
- **FILM NUMBER:** 251065411

**BUSINESS ADDRESS:**
- **STREET 1:** 2929 N COMMERCE PKWY
- **CITY:** MIRAMAR
- **STATE:** FL
- **ZIP:** 33025
- **BUSINESS PHONE:** 954-842-2024

**MAIL ADDRESS:**
- **STREET 1:** 2929 N COMMERCE PKWY
- **CITY:** MIRAMAR
- **STATE:** FL
- **ZIP:** 33025

?xml version='1.0' encoding='ASCII'? 8-K

**UNITED STATES SECURITIES AND EXCHANGE COMMISSION WASHINGTON, D.C. 20549**

------

## **FORM** 8-K

------

**CURRENT REPORT**

**Pursuant to Section 13 or 15(d) of the Securities Exchange Act of 1934**

**Date of Report (Date of earliest event reported):** June 17, 2025<br>

------

HCW Biologics Inc.

**(Exact name of Registrant as Specified in Its Charter)**

------

---

| | | |
|:---|:---|:---|
| Delaware | 001-40591 | 82-5024477 |
| **(State or Other Jurisdiction<br>of Incorporation)** | **(Commission File Number)** | **(IRS Employer<br>Identification No.)** |
| 2929 N. Commerce Parkway |  |  |
| Miramar**,** Florida |  | 33025 |
| **(Address of Principal Executive Offices)** |  | **(Zip Code)** |

---

**Registrant's Telephone Number, Including Area Code:** 954 842-2024<br>

**(Former Name or Former Address, if Changed Since Last Report)**

------

Check the appropriate box below if the Form 8-K filing is intended to simultaneously satisfy the filing obligation of the registrant under any of the following provisions:

☐Written communications pursuant to Rule 425 under the Securities Act (17 CFR 230.425)

☐Soliciting material pursuant to Rule 14a-12 under the Exchange Act (17 CFR 240.14a-12)

☐Pre-commencement communications pursuant to Rule 14d-2(b) under the Exchange Act (17 CFR 240.14d-2(b))

☐Pre-commencement communications pursuant to Rule 13e-4(c) under the Exchange Act (17 CFR 240.13e-4(c))

**Securities registered pursuant to Section 12(b) of the Act:**

---

| | | |
|:---|:---|:---|
| **<br>Title of each class** | **Trading<br>Symbol(s)** | **<br>Name of each exchange on which registered** |
| Common Stock, par value $0.0001 per share | HCWB | The Nasdaq Stock Market LLC |

---

Indicate by check mark whether the registrant is an emerging growth company as defined in Rule 405 of the Securities Act of 1933 (§ 230.405 of this chapter) or Rule 12b-2 of the Securities Exchange Act of 1934 (§ 240.12b-2 of this chapter).

Emerging growth company ☒

If an emerging growth company, indicate by check mark if the registrant has elected not to use the extended transition period for complying with any new or revised financial accounting standards provided pursuant to Section 13(a) of the Exchange Act. ☒

------

**Introductory Note:**

On June 17, 2025, HCW Biologics Inc. (the "Company"), held its 2025 Annual Meeting of Stockholders (the "Annual Meeting"). During the meeting, the Company's service provider experienced technical difficulties that may have prevented the Company's stockholders from logging into the virtual meeting; however, many stockholders were able to join via phone. The replay of the Annual Meeting will be available for one year at https://www.virtualshareholdermeeting.com/HCWB2025, and through July 31, 2025, stockholders may submit questions that they otherwise might have submitted at the Annual Meeting to: info@hcwbiologics.com. Questions that follow the Meeting guidelines will be answered in a publicly available format.

## **Item 5.02 Departure of Directors or Certain Officers; Election of Directors; Appointment of Certain Officers; Compensatory Arrangements of Certain Officers.** 
On June 17, 2025, after the Annual Meeting, HCW Biologics Inc. accepted Gary M. Winer's resignation from the Company's Board of Directors, effective immediately. The Board of Directors is not required to fill the seat on the Board of Directors formerly held by Mr. Winer, and thus, this seat will remain vacant.

## **Item 5.07 Submission of Matters to a Vote of Security Holders.** 
On June 17, 2025, after the adjournment of the Annual Meeting, the Company accepted Gary M. Winer's resignation from the Company's Board of Directors, effective immediately. Mr. Winer's resignation was not due to any disagreement with the Company on any matter relating to the Company's operations, policies, or practices. The Board of Directors has determined not to appoint a replacement director currently.

&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;1.At the Annual Meeting, the Company's stockholders elected the persons listed below as Class I directors for three-year terms expiring at the 2028 Annual Meeting of Stockholders or until their respective successors are duly elected and qualified:

---

| | | | |
|:---|:---|:---|:---|
| **Nominee** | **For** | **Withheld** | **Broker Non-Votes** |
| Scott T. Garrett | 534,541 | 9,185 | 150,771 |
| Gary M Winer | 133,365 | 410,361 | 105,771 |

---

&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;2.The Company's stockholders ratified the appointment of Crowe LLP as the independent registered public accounting firm of the Company for the fiscal year ending December 31, 2025.

---

| | | | |
|:---|:---|:---|:---|
| &nbsp;&nbsp;**For** | **Against** | **Abstain** | **Broker Non-Votes** |
| &nbsp;&nbsp;693,874 | 595 | 28 | -- |

---

## **Item 8.01 Other Events.** 
During the Annual Meeting, the Company's service provider, Broadridge Financial Solutions, Inc., experienced technical difficulties that may have prevented stockholders from joining the virtual meeting; however, a quorum at the Annual Meeting was reached through the attendance in person or by proxy of persons, who, as of the record date of April 22, 2025, held a majority of the voting power of the shares of our common stock entitled to vote at the Annual Meeting. Accordingly, The Annual Meeting was validly held.

Broadridge will send a letter to the Company's stockholders that includes links to the replay of the Annual Meeting and a platform where stockholders can submit questions. A copy of this letter is furnished as Exhibit 99.1 to this Form 8-K. The Company has also posted the letter on its investor website at: https://investors.hcwbiologics.com/.

------

## **Item 9.01 Financial Statements and Exhibits.** 
(d) Exhibits

---

| | |
|:---|:---|
| **<u>Exhibit No.</u>** | **<u>Description</u>** |
| 99.1 | [<u>Letter to HCW Biologics Inc. Stockholders dated June 23, 2025.</u>](hcwb-ex99_1.htm) |
| 104 | Cover Page Interactive Data File (embedded within the Inline XBRL document). |

---

------

**SIGNATURES**

Pursuant to the requirements of the Securities Exchange Act of 1934, the registrant has duly caused this report to be signed on its behalf by the undersigned hereunto duly authorized.

---

| | | | |
|:---|:---|:---|:---|
|  |  |  | **HCW BIOLOGICS INC.** |
| Date: | June 23, 2025 | By:  | /s/ Hing C. Wong |
|  |  |  | Hing C. Wong, Founder and Chief Executive Officer |

---

------

## Exhibit 99.1

**Exhibit 99.1**

![img90053791_0.jpg](img90053791_0.jpg)

June 23, 2025

Dear Stockholder,

We would like to inform you that, after the conclusion of our Annual Stockholder Meeting, our provider, Broadridge Financial Solutions Inc., advised us that it had encountered technical difficulties during the live webcast of our Meeting on June 17, 2025. Unfortunately, their issue prevented some of you from logging in and participating as we had intended. Broadridge extends its apology for any inconvenience or frustration this may have caused to you and to us.

To ensure all stockholders have access to the information and discussions presented at the Meeting, we have made a full replay of the Meeting available. Whether you were unable to participate live or would simply like to revisit the proceedings, you can view the recording at your convenience by visiting: www.virtualshareholdermeeting.com/HCWB2025. Additionally, if you are a stockholder and were unable to submit a question for us during our Annual Stockholder Meeting, you may submit your question at info@hcwbiologics.com.

We greatly appreciate your continued support and thank you for your engagement as valued members of our stockholder community.

Sincerely,

HCW Biologics Inc.

------